Jazz Pharma (JAZZ) Raises FY12 Outlook
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $107.43 -0.82%
Revenue Growth %: +7.1%
Financial Fact:
Selling, general and administrative: 124.37M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Revenue Growth %: +7.1%
Financial Fact:
Selling, general and administrative: 124.37M
Today's EPS Names:
FRSB, DGICA, UXIN, More
Join SI Premium – FREE
Jazz Pharma (Nasdaq: JAZZ) raised its FY12 EPS guidance to $4.25-$4.40 on sales of $500-$510 million. The Street is currently looking for FY12 EPS of $4.45 on sales of $516.75 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024
- Hub Group, Inc. (HUBG) Tops Q1 EPS by 5c, provides guidance
- Carlisle Cos. (CSL) Tops Q1 EPS by 91c, Beats on Revenue; Offers FY24 Outlook
Create E-mail Alert Related Categories
GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
